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Proteinaceous inclusion bodies (IBs) are common features
of neurodegenerative proteinopathies, and their roles in
pathogenesis are frequently debated. This is true for Hun-
tington disease (HD), which exhibits both intranuclear and
cytoplasmic IBs composed primarily of mutant protein. The
initial recognition of IBs in HD prompted speculation that
they drove neurodegeneration. An alternative explanation,
supported by sophisticated experimental work and correla-
tive striatal pathologic studies, was that IBs represent pro-
tective “sinks” sequestering toxic soluble protein species.1,2
B€auerlein and colleagues3 report high-resolution analysis of
intracellular polyglutamine (polyQ) containing inclusion bod-
ies. Technical advances in cryo-electron tomography allow
remarkably resolute visualization of subcellular structures in
situ, permitting inferences about physiologic roles or, as in
this case, the pathologic effects of specific structures.
B€auerlein and colleagues visualized IBs in cells transfected
with expanded polyQ exon 1 huntingtin (htt) constructs. IBs
consisted of amyloid-like fibrils apparently interacting with
cellular endomembranes, particularly endoplasmic reticulum
(ER) membranes. B€auerlein and colleagues present interest-
ing data suggesting that cytoplasmic IBs exert deleterious
effects on ER function, consistent with prior suggestions that
disrupted ER function is a contributing feature to neurode-
generation in HD.
There are limitations of this technically impressive and
visually beautiful work. These are results from overexpres-
sion in the in vitro cell models. Although some data derived
from cultured neurons, much was obtained in nonneuronal
HeLa cells. The constructs used did not produce full-length
htt. Further work in more realistic models will be needed to
extend these observations.
It is important to see this work in a broader context.
There are several well-supported potential mechanisms of
neurodegeneration secondary to expanded polyQ htt. Both
gain of function toxicities and haploinsufficiency effects may
play roles in neurodegeneration. Transcriptional dysregulation,
axonal transport defects, mitochondrial dysfunction, aberrant
intracellular calcium homeostasis, RNA toxicity, and excito-
toxicity, among others, have credible experimental support.
This suggests that expanded repeat polyQ htt has pleiotropic
neurotoxic effects, including via soluble protein species. It is
plausible that HD IBs act both as protective sinks and have
toxic effects.4
Some of the data from B€auerlein and colleagues are con-
sistent with this last suggestion. They report that nuclear IBs
were not associated with endomembranes. Prior experimen-
tal data indicates that nuclear localization of expanded
polyQ htt is important in neurodegeneration. It is plausible
that nuclear IBs are protective, whereas some cytoplasmic
IBs cause ER dysfunction.
The more we learn about the biology of expanded polyQ
htt, the more complex the pathogenesis of HD seems.
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